Latest BioAge Labs News & Updates

See the latest news and media coverage for BioAge Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioAge Labs

Biotechnology company developing therapies for cardiometabolic diseases

bioagelabs.com

Headquarters: Emeryville, United States
Founded year: 2015
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated September 22

Latest news about BioAge Labs

In short: BioAge Labs advanced BGE-102 into Phase 2 trials for cardiovascular risk and diabetic macular edema.

Company announcements

August 5 BioAge Labs

BioAge Labs reports Q2 2026 results and BGE-102 progress

First participant dosed in Phase 2 QUELL-CV; topline data expected in H2 2026, with Q2 net loss of $26.1 million.

May 8 BioAge Labs

BioAge Labs reports Q1 2026 financial results

Positive Phase 1 data for BGE-102 shown. Phase 2 trials planned for mid-2026. $132.3M raised via offering. Net loss $22.3M.

April 21 BioAge Labs

BioAge reports positive Phase 1 data for BGE-102

BGE-102 achieves ≥85% median hsCRP reductions at 60 mg and 120 mg doses in obese participants. Well tolerated. Phase 2 trials in cardiovascular risk and DME planned for mid-2026.

March 24 BioAge Labs

BioAge Labs reports 2025 financial results

Announces positive Phase 1 data for BGE-102, plans Phase 2 trials, completes $132.3M offering. Cash funds operations through 2029.

Media coverage

September 22 Longevity Technology

BioAge tests an aging pathway against eye disease

The first patient has been dosed in a Phase 2 trial of BGE-102, an oral pill built on human aging research, aimed at preserving vision.

August 11 American Banker

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - American Market News

Renaissance Technologies LLC boosted its stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA – Free Report) by 653.2% in the 1st quarter, according to its...

August 5 L'Observateur

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business...

Small Business | L'Observateur...

August 3 Seeking Alpha

BioAge Labs posts partial recovery after deep selloff, rises 19%

(BIOA) rebounds after a 64% plunge tied to Novo's ZEUS trial failure—see key metrics, NLRP3 read-through risk, and what to watch next.

Never miss news about BioAge Labs

Track BioAge Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioAge Labs competitors & trending companies

Browse news for competitors to BioAge Labs and other trending companies.